GAMMA Investing LLC Has $276,000 Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

GAMMA Investing LLC boosted its stake in IQVIA Holdings Inc. (NYSE:IQV) by 27.7% in the fourth quarter, HoldingsChannel reports. The firm owned 1,406 shares of the medical research company’s stock after acquiring an additional 305 shares during the period. GAMMA Investing LLC’s holdings in IQVIA were worth $276,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the stock. Private Advisor Group LLC increased its position in shares of IQVIA by 8.1% in the 2nd quarter. Private Advisor Group LLC now owns 5,078 shares of the medical research company’s stock valued at $1,074,000 after buying an additional 379 shares in the last quarter. Acadian Asset Management LLC raised its position in shares of IQVIA by 110.7% during the second quarter. Acadian Asset Management LLC now owns 7,078 shares of the medical research company’s stock worth $1,496,000 after purchasing an additional 3,718 shares during the period. Caprock Group LLC lifted its holdings in shares of IQVIA by 24.6% during the 2nd quarter. Caprock Group LLC now owns 2,688 shares of the medical research company’s stock valued at $568,000 after purchasing an additional 530 shares in the last quarter. Quest Partners LLC increased its stake in IQVIA by 1,656.7% during the 2nd quarter. Quest Partners LLC now owns 4,620 shares of the medical research company’s stock worth $977,000 after purchasing an additional 4,357 shares in the last quarter. Finally, First Foundation Advisors raised its holdings in IQVIA by 3.8% during the 2nd quarter. First Foundation Advisors now owns 1,161 shares of the medical research company’s stock worth $245,000 after buying an additional 43 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on IQV. William Blair reissued an “outperform” rating on shares of IQVIA in a research report on Wednesday, December 11th. JPMorgan Chase & Co. dropped their price target on IQVIA from $279.00 to $240.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 5th. Robert W. Baird reduced their price objective on IQVIA from $213.00 to $212.00 and set a “neutral” rating for the company in a research report on Wednesday, December 11th. Leerink Partners reissued an “outperform” rating and issued a $248.00 target price (down previously from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. Finally, Barclays decreased their price target on shares of IQVIA from $260.00 to $255.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. Four analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $255.82.

IQVIA Stock Performance

Shares of NYSE IQV opened at $202.63 on Wednesday. IQVIA Holdings Inc. has a 12 month low of $187.62 and a 12 month high of $261.73. The stock has a 50 day moving average of $202.22 and a 200-day moving average of $221.94. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76. The company has a market capitalization of $36.78 billion, a P/E ratio of 26.59, a P/E/G ratio of 2.05 and a beta of 1.48.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.